Astrazeneca (NYSE:AZN) told investors and analysts that it is continuing to embed sustainability into its business strategy while updating some of its 2030 targets to reflect growth and lessons learned from existing programs.
During the company’s 2026 Sustainability Update, Pam Cheng, EVP Global Op